SEARCH

SEARCH BY CITATION

References

  • 1
    National Institute of Health consensus development conference statement: management of hepatitis C. HEPATOLOGY 2002; 36: S3S20.
  • 2
    Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958956.
  • 3
    Fried MW, Schiffman ML, Reddy KR, Smith C, Marinos G, Gonzales FL, et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 4
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 5
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N.Engl J Med 2005; 352: 26092617.
  • 6
    Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 12601265.
  • 7
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. PegInterferon alpha 2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 and 3 chronic hepatitis C. HEPATOLOGY 2001; 34: 395403.
  • 8
    Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553559.
  • 9
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solà, et al. Peginterferon alfa-2a and Ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124134.
  • 10
    Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. J Hepatol 2005; 42: 275278.
  • 11
    Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3 J Hepatol 2004; 40: 993999.
  • 12
    Powis J, Peltekian M, Lee SS, Sherman M, Bain VG, Cooper C, et al. Exploring differences in response to treatment with peginterferon alpha 2a and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepatol 2008; 18: 5257.
  • 13
    Andriulli A, Dalgard O, Bjoro K, Mangia A. Short-term treatment duration for HCV- 2 and HCV-3 infected patients. Dig Liv Dis 2006; 38: 741748.
  • 14
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372374.
  • 15
    Iacobellis A, Mangia A, Leandro G, Clemente R, Festa V, Attino V, et al. External validation of biochemical indices for non invasive evaluation of liver fibrosis in HCV chronic hepatitis. Am J Gastroenterol 2005; 100: 868887.
    Direct Link:
  • 16
    McHutchison JG, Manns M, Patel E, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype 1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 17
    Hoofnagle JH, Seef LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 24442451.
  • 18
    Liang TJ. Shortened therapy for hepatitis C virus genotype 2 or 3: is less more? N Engl J Med 2007; 357: 176178.
  • 19
    Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. HEPATOLOGY 2008; 47: 3542.
  • 20
    Shiffman ML, Suter F, Bacon BR, Nelson DR, Harley H, Sola R, et al. Peginterferon plus ribavirin for 16 or 24 weeks in patients with HCV genotype 2/3 infection and advanced fibrosis/cirrhosis. Gastroenterology 2007; 32: 728.
  • 21
    Way CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marreo JA, Conjeevaram HS, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518526.
  • 22
    Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55: 529535.
  • 23
    Mangia A, Koleva D, De Compadri P, Garattini L. Cost minimization analysis of peginterferon alfa-2b + ribavirin, 12 weeks versus 24 weeks. JME 2008; 11: 151163.